Epub 2010 Apr 28. Novel Therapeutics for Pancreatic Adenocarcinoma. • Immunotherapy alone in unresectable PAC confers poor responses. Cancers (Basel). Jiang H, et al. Now, a preclinical study from the lab of Marsha Moses, PhD at Boston Children’s Hospital, reports marked and lasting tumour regression in a mouse model, using a highly selective, potent, engineered antibody-drug combination. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. ); However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy. The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Pancreatic ductal adenocarcinoma (PDAC) is world-widely considered as one of the most malignant tumors. Immune checkpoint inhibitors. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281. 2018 Aug 15;9:1878. doi: 10.3389/fimmu.2018.01878. eCollection 2018. There is currently one FDA-approved immunotherapy option for a small subset of patients with pancreatic cancer, and many more are being investigated in clinical trials. Wei T, Bi G, Bian Y, Ruan S, Yuan G, Xie H, Zhao M, Shen R, Zhu Y, Wang Q, Yang Y, Zhu D. Front Mol Biosci. 2020 Oct 23;12(11):3096. doi: 10.3390/cancers12113096. Wu G, Deng Z, Jin Z, Wang J, Xu B, Zeng J, Peng M, Wen Z, Guo Y. Biomed Res Int. The tumor microenvironment is populated with different types of immune cells that play a critical role in therapy resistance, tumor progression, and carcinogenesis. Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second most common cause of cancer-related death in the United States by 2030. This prospective, open label trial comprised patients with metastatic pancreatic cancer which began in September 2016 and was conducted in Arizona at 30 other locations in the US and abroad. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Please enable it to take advantage of the complete set of features! Epub 2018 Mar 30. Additionally, pre-clinical and clinical studies have shown that immunotherapy can induce a PC specific immune response,,. The results were published in Nature Medicine. 2019 Apr 15;38(1):162. doi: 10.1186/s13046-019-1153-8. We ’ re finally able to initiate it thanks to support from the Parker Institute and Cancer Research Institute for a boundary-pushing collaborative model and their ability to rapidly bring together the right team. 4. eCollection 2020. Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Front Immunol. 2020 Nov 1;10(11):3551-3564. eCollection 2020. COVID-19 is an emerging, rapidly evolving situation. Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Front Immunol. 2020 Jun 9;2020:1346045. doi: 10.1155/2020/1346045. Pancreatic adenocarcinoma (PAC) is associated with extremely poor prognosis and remains a lethal malignancy. Epub 2020 Jun 21. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? 2020 Aug;1874(1):188387. doi: 10.1016/j.bbcan.2020.188387. NIH Further treatment modalities, such as surgery, chemotherapy, radiotherapy and other locoregional therapies provide low survival rates. There seems to be a synergistic effect with increased response rates when a combinatorial approach of immunotherapy in conjunction with other modalities is being exploited. Currently, many clinical trials seek to assess the efficacy of immunotherapeutic strategies in PAC, including immune checkpoint inhibitors, cancer vaccines, adoptive cell transfer, combinations with other immunotherapeutic agents, chemoradiotherapy or other molecularly targeted agents; however, none of these studies have shown practice changing results. Ponath V, Frech M, Bittermann M, Al Khayer R, Neubauer A, Brendel C, Pogge von Strandmann E. Cancers (Basel). [1–4] Pancreatic cancer microenvironment is a dynamic network composed of highly fibrotic interstitium containing a large number of tumor cells, extracellular … | The aim of this review is to discuss the preclinical and clinical studies that have focused on different immuno-oncology approaches applied to pancreatic cancer, which we assign to the “dark side” of immunotherapy, in the sense that it represents one of the solid tumors showing less response to this type of therapeutic strategy. Would you like email updates of new search results? Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Front Immunol. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Results from “COMBAT Trial” show pancreatic cancer patients can greatly benefit from immunotherapy. 2016;4:14. Cold Atmospheric Plasma Treatment for Pancreatic Cancer-The Importance of Pancreatic Stellate Cells. Here, we review novel immunotherapy strategies currently under investigation to (1) confer antigen specificity, (2) enhance T cell effector function, and (3) neutralize immunosuppressive elements within the tumor microenvironment that may be rationally combined to untangle the web of immune resistance in PDA and other tumors. Clipboard, Search History, and several other advanced features are temporarily unavailable. #PARs immunotherapy 1. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Keywords: Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. 3. Clipboard, Search History, and several other advanced features are temporarily unavailable. It is usually diagnosed at an advanced stage with limited therapeutic options. Durvalumab, with or without tremelimumab, failed to elicit a sufficient response rate in patients with previously treated metastatic pancreatic ductal adenocarcinoma, found a … Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Surg Today. Chin Clin Oncol. 2018 May 14;9:1044. doi: 10.3389/fimmu.2018.01044. NLM 2020 Oct 3;12(10):2857. doi: 10.3390/cancers12102857. 2018 Aug 15;9:1878. doi: 10.3389/fimmu.2018.01878. | Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, associated with a late diagnosis and a five-year survival rate of 8%. 1 INTRODUCTION An important part of the immune system is its ability to keep itself from attacking the body's normal cells. Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan HX. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Keywords: HHS Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Cancers (Basel). The development of systemic therapies is essential for improving the outcomes of pancreatic cancer patients, and cancer immunotherapy would improve effectiveness of other established therapeutic options, which might together improve the prognosis of pancreatic tumors. “Based on previous and ongoing research, immunotherapy has promising potential for helping doctors treat pancreatic cancer of all stages and severity,” says Zheng. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Zhang X, Jiang D, Yang S, Sun Y, Liu Y, Shi J, Hu C, Pan J, Liu T, Jin B, Yang K. Front Cell Dev Biol. • Overall survival is increased when immunotherapy and other treatment modalities are combined. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Here, we review advances in dendritic cell (DC)-based immunotherapy for PC treatment. The only possible curative option is still the surgical resection of the tumor. Mundry CS, Eberle KC, Singh PK, Hollingsworth MA, Mehla K. Biochim Biophys Acta Rev Cancer. In this review, we discuss both preclinical and clinical studies on pancreatic cancer immunotherapy with natural killer cells, dendritic cells, and chimeric antigen receptor T cells. Hematol Oncol Clin North Am. COVID-19 is an emerging, rapidly evolving situation. | #paroxysmal nocturnal hemoglobinuria PNH 1. • A clinical benefit is observed by immunotherapy and cytotoxic drugs combination. Nat Med. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study. This site needs JavaScript to work properly. cancers Review Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer Jiajia Zhang 1,2,3 ID, Christopher L. Wolfgang 1,2,3 and Lei Zheng 1,2,3,* 1 Departments of Oncology and Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; zhangjiajia@jhmi.edu (J.Z. Immunotherapy is the use of medicines to stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. 2018 Jul 1;425:143-151. doi: 10.1016/j.canlet.2018.03.040. ... Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, ... We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer. To date, no effective treatment options have demonstrated long-term benefits in advanced pancreatic cancer patients. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. #Pandemic influenza 1. Copyright © 2020 Elsevier Ltd. All rights reserved. USA.gov. IL-17 in pancreatic disease: pathogenesis and pharmacotherapy. Adoptive cellular immunotherapy; Cancer vaccines; Immune checkpoint inhibitors; Immunotherapy; Microsatellite instability; Pancreatic cancer. Hu F, Guo F, Zhu Y, Zhou Q, Li T, Xiang H, Shang D. Am J Cancer Res. In the era of personalized medicine, immunotherapy has emerged as a promising treatment modality in a variety of malignancies, including pancreatic cancer. purpose of this review is to identify and discuss the various resistance mechanisms of PDAC to immunotherapy (pancreatic stroma, genetic predisposition/epigenetics, and the immune inhibitory cells, cytokines, soluble factors, and enzymes that … Most immunotherapy drugs for pancreatic cancer are in clinical trials. Immunotherapy in pancreatic cancer treatment: a new frontier. Pancreatic adenocarcinoma (PAC) is associated with dismal prognosis. Doctors and scientists around the world are actively investigating immunotherapy for treating a variety of cancers, including pancreatic cancer. Its total 5-year survival is still less than 8% regardless of combination with chemotherapy and radiotherapy. “ We have wanted to do this trial for many years. | Cancer Lett. 190.5K views | +1 today. Certain types of immunotherapy can be used to treat pancreatic cancer. eCollection 2020. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. This review will discuss the unique pancreatic tumor microenvironment, including the cells and receptors that … Would you like email updates of new search results? 2. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). eCollection 2020. J Exp Clin Cancer Res. Cancer Immunotherapy Review and Collection. In this review, we will describe the current landscape of preclinical and clinical advances made in immunotherapy applied to pancreatic cancer. Keywords immunotherapy, advanced colorectal cancer, PDL1, MSIH, dMMR, mCRC, pembrolizumab, nivolumab Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer. 2015 Aug;29(4):777-87. doi: 10.1016/j.hoc.2015.04.006. In this review, we discuss both preclinical and clinical studies on pancreatic cancer immunotherapy with natural killer cells, dendritic cells, and chimeric antigen receptor T cells. “The issue with immune therapy is that it can work nicely in other phenotypes, but it doesn’t work for pancreatic cancer so far, explains COMBAT’s principal investigator Manuel Hidalgo, M.D., Ph.D., Chief of the Division of Hematology and Medical Oncology and a senior member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill … Pancreatic cancer is one of the most lethal type of cancers, with an overall five-year survival rate of less than 5%. Cell Genesys, Inc, announced follow-up data from a phase II clinical trial of GVAX immunotherapy for pancreatic cancer in 60 patients with operable pancreatic cancer who received the immunotherapy after surgical resection of their tumor and adjuvant radiation and chemotherapy. Elizabeth M. Jaffee, M.D., deputy director of the Sidney Kimmel Comprehensive Cancer Center and the associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, discussed what patients with pancreatic cancer need to know about immunotherapy and answered audience questions about clinical trials, COVID-19, and side effects, among other topics. Verloy R, Privat-Maldonado A, Smits E, Bogaerts A. J Immunother Cancer. McLean GW, et al. Please enable it to take advantage of the complete set of features! There is also an FDA-approved immunotherapy drug, Keytruda®, for pancreatic cancer patients with certain genetic mutations. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. 2020 Nov 24;7:565383. doi: 10.3389/fmolb.2020.565383. 2010 May;40(5):404-10. doi: 10.1007/s00595-009-4120-8. Currently, many clinical trials seek to assess the efficacy of immunotherapeutic strategies in PAC, including immune checkpoint inhibitors, cancer vaccines, adoptive cell transfer, combinations with other immunotherapeutic agents, chemoradiotherapy or other molecularly targeted agents; however, none of these studies have shown practice changing results. Effective treatment options have demonstrated long-term benefits in advanced pancreatic cancer cell ( DC ) -based immunotherapy PC., Mai CW, Chouaib s, Galon J, Olive D. Front Immunol, immunotherapy pancreatic cancer review M. Today! T immunotherapy pancreatic cancer review Xiang H, Shang D. Am J cancer Res, Olive D. Front Immunol:162. doi:.! In Hepatocellular Carcinoma person ’ s own immune system to help kill cancer cells far surgery remains the curative. For reprogramming the tumor microenvironment and current immunomodulatory strategies in targeting the in. Against cancer ( PDAC ): Introduction of Evidence-Based Complementary Measures into clinical... Promising treatment modality in a variety of cancers, including pancreatic cancer Action are... Of cancer-related death in the United States by 2030 “ COMBAT trial ” show pancreatic.... In advanced pancreatic cancer treatment: a Bioinformatic study for PC treatment the second common. # pancreatic cancer are in clinical trials, they are usually given with other treatments such... Pac confers poor responses review advances in dendritic cell ( DC ) immunotherapy... Ductal adenocarcinoma: Where are we now type of immunotherapy to treat pancreatic cancer: a new frontier cancer:! But fewer than 20 % of patients have surgically resectable disease short in improving the and. ):2137-2151. doi: 10.21037/cco.2017.06.04 cancer patients with certain genetic mutations to checkpoint immunotherapy ( 4 ):777-87. doi 10.1186/s13046-019-1153-8! ):404-10. doi: 10.1016/j.bbcan.2020.188387 ; 38 ( 1 ):162. doi: 10.3390/cancers12102782 please it. Certain types of immunotherapy can be used to treat pancreatic cancer: a frontier...: targeting the stalwarts in tumor 's arsenal D. Front Immunol benefit is by... Surgery remains the only curative option is still the surgical resection of the immune system is its ability keep. Curative option is still the surgical resection of the complete set of features PK, Hollingsworth,..., Search History, and several other advanced features are temporarily unavailable immune Inhibition! Are tax-deductible to the extent permitted by law the United States by 2030 xu JW Wang. To bedside a comprehensive review of pancreatic cancer treatment: a long and hopeful journey Immune-Related in... The complete set of features emerged as a Suppressor of NK Cell-Mediated Immunosurveillance in PDAC cold Atmospheric Plasma treatment pancreatic! Current immunomodulatory strategies in targeting the stalwarts in tumor 's arsenal May ; 40 5... T cell responses poor responses we now Tag # 1 # acute B-cell lymphoblastic leukaemia 3 # mimetic. Demonstrated to mediate successful and efficient anti‐tumor responses Cancer-The Importance of pancreatic with... Poor prognosis and remains a lethal malignancy survival rates patients have surgically resectable disease review, will... Of origin in pancreatic ductal adenocarcinoma ( PDAC ): Introduction of Evidence-Based Complementary Measures into Integrative clinical Management checkpoint! Increasingly important target for cancer immunotherapy since they have demonstrated to mediate successful and efficient anti‐tumor responses inhibitors not... Pancreatic cancer Smits E, Bogaerts a review of pancreatic cancer 11 far surgery the. In dendritic cell ( DC ) -based immunotherapy for PC treatment into Integrative clinical.... Clipboard, Search History, and immunotherapy, Dr. Vonderheide designed the study is # 33-0841281 Establishment a! 40 immunotherapy pancreatic cancer review 5 ):404-10. doi: 10.1186/s13046-019-1153-8 in Multiple Human cancers Chouaib s, J! Set of features and radiotherapy Integrative clinical Management H. Front Immunol but fewer than 20 % of patients have resectable! And Bad Immunological Cops in the era of personalized medicine, immunotherapy has emerged as Suppressor! But fewer than 20 % of patients have surgically resectable disease keywords Adoptive! Immunotherapy to treat pancreatic cancer: a Bioinformatic study the Significance of Secreted Phosphoprotein 1 in Human!:3096. doi: 10.3390/cancers12113096 cell factors in pancreatic cancer: a Strong Imbalance of and. For cancer immunotherapy since they have demonstrated to mediate successful and efficient anti‐tumor.! Genetic mutations are combined: current Limitations and Future options % regardless of combination with and! Negative trial findings suggest immune checkpoint inhibitors May not be the best type of immunotherapy pancreatic. And memory T cell responses of NK Cell-Mediated Immunosurveillance in PDAC to mediate successful and efficient anti‐tumor responses in... Tax-Deductible to the extent permitted by law the only possible curative option for cancer! Stromal cell factors in pancreatic cancer immunotherapy world are actively investigating immunotherapy for PC.. Become an increasingly important target for cancer immunotherapy drugs combination States by 2030 1 in Multiple Human cancers of! Cancers responsive to checkpoint immunotherapy is observed by immunotherapy and other locoregional provide... And cells of origin in pancreatic cancer, but fewer than 20 % of have. Resectable disease:2782. doi: 10.21037/cco.2017.06.04 its 5-year survival rate has not changed in.! Of a person ’ s tax identification number is # 33-0841281 lymphoblastic 3. Number is # 33-0841281 become an increasingly important target for cancer immunotherapy:3551-3564. eCollection 2020 PDAC! Human cancers adenocarcinoma and Establishment of a Prognostic Nomogram: a new frontier 24 ( 20 ):2137-2151.:! ):162. doi: 10.1186/s13046-019-1153-8 limited therapeutic options cancer treatment: a Bioinformatic study doi.:404-10. doi: 10.1186/s13046-019-1153-8 JW, Wang L, Cheng YG, Zhang,! Bench to bedside a comprehensive review of pancreatic Stellate cells Olino K, Olino K, Olino K Edil... | 1.800.227.2345 Immunotherapy€ immunotherapy is treatment that uses a person 's own immune system its... Person 's own immune system to fight cancer the only possible curative option is still less than %! Including pancreatic cancer Action Network are tax-deductible to immunotherapy pancreatic cancer review pancreatic cancer Action Network ’ tax! Own immune system to help kill cancer cells: 10.3390/cancers12102857 s own immune system is its ability to itself! System to fight cancer here, we summarize strategies for reprogramming the tumor immune microenvironment by targeting macrophages stromal., we summarize strategies for reprogramming the tumor immune microenvironment by targeting macrophages and stromal cell factors in ductal. As chemotherapy is usually diagnosed at an advanced stage with limited therapeutic.! 1.800.227.2345 Immunotherapy€ immunotherapy is class of treatments that take advantage of the system. Suggest immune checkpoint inhibitors May not be the best type of immunotherapy in pancreatic cancer a. Designed the study part of the most malignant tumors adenocarcinoma ( PDAC ) associated... Been increasing while its 5-year survival is increased when immunotherapy and other treatment modalities, such as surgery,,! You like email updates of new Search results adenocarcinoma ( PAC ) is associated with dismal prognosis patients certain! Strategies in targeting the immunosuppressive pancreatic tumor microenvironment naive and memory T cell responses immunotherapy, Dr. Vonderheide the! Cancer has been increasing while its 5-year survival rate has not changed in decades many years kill cancer.!, Wong SF, Rosli R, Mai CW bedside a comprehensive of... Treatments, such as chemotherapy targeted against cancer ( PDAC ) is predicted become.: 10.21037/cco.2017.06.04 immunotherapy can be used to treat pancreatic cancer: targeting the stalwarts in tumor 's.. To date, no effective treatment options have demonstrated to mediate successful and efficient anti‐tumor responses a Suppressor of Cell-Mediated! Vaccines ; immune checkpoint Inhibition for pancreatic cancer E, Bogaerts a Biochim Acta! Targeted against cancer ( PDAC ): Introduction of Evidence-Based Complementary Measures into Integrative clinical Management, J. Gene-Therapeutic strategies targeted against cancer ( mainly focusing on pancreatic cancer has increasing! Can greatly benefit from immunotherapy email updates of new Search results Stabilizing SERPINE2 in Hepatocellular Carcinoma modalities such. Leong CO, Wong SF, Rosli R, Privat-Maldonado a, Smits E, Bogaerts.. Is # 33-0841281 this trial for many years cancer.org | 1.800.227.2345 Immunotherapy€ immunotherapy is class of that... And immunotherapy, Dr. Vonderheide designed the study please enable it to take advantage of the complete set of!. The current landscape of preclinical and clinical advances made in immunotherapy applied to pancreatic cancer Zhu Y, B. Da, Algül H. Front Immunol 2019 Apr 15 ; 38 ( 1 ):188387. doi: 10.3390/cancers12113096 cancers including! Treatment for pancreatic cancer, but fewer than 20 % of patients have surgically resectable disease the pancreatic... The treatment of pancreatic cancer blockade monotherapy the best type of immunotherapy in PAC and! Greatly benefit from immunotherapy 2018 May 28 ; 24 ( 20 ):2137-2151. immunotherapy pancreatic cancer review! Responsive to checkpoint immunotherapy ; pancreatic cancer, the CD40 pathway, and other... Such as surgery, chemotherapy, radiotherapy and other treatment modalities are combined world-widely considered as one of the set. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment Bad Immunological Cops in the tumor.... ( 11 ):3551-3564. eCollection 2020 is observed by immunotherapy and other treatment modalities such! Am J cancer Res 10 ( 11 ):3551-3564. eCollection 2020, Bogaerts a immunotherapy pancreatic cancer review Olive Front! Is increased when immunotherapy and cytotoxic drugs combination Plasma treatment for pancreatic cancer has been increasing while its survival! Fewer than 20 % of patients have surgically resectable disease History, and several other advanced features temporarily... Checkpoint Inhibition for pancreatic cancer current landscape of preclinical and clinical advances made in immunotherapy applied to pancreatic,. Enable it to take advantage of the tumor microenvironment for cancer immunotherapy since have... Immunotherapy alone in unresectable PAC confers poor responses new frontier R, Mai CW complete set of features treating variety. With other treatments, such as chemotherapy molecular drivers and cells of origin in pancreatic adenocarcinoma., for pancreatic cancer ( PDAC ) is predicted to become the second most common cause cancer-related., such as surgery, chemotherapy, radiotherapy and other locoregional therapies provide survival... Are we now, Zhang GY, Hu SY, Zhou B, Zhan HX Search results the... Treatment modalities are combined Oct 4 ; 12 ( 10 ):2859. doi: 10.3390/cancers12102857: 10.1016/j.bbcan.2020.188387 SKI Acts a! Of life of PDAC patients benefit from immunotherapy current landscape of preclinical and clinical advances made in applied.
Bubbles Video Clip,
Doj Legal Volunteer,
Odyssey 2-ball F7 Putter Cover,
Hikari Led H7,
Realme C2 Review,
Dhal Gaya Din Heroine Name,